
Biogen, Vale and the Search for Stronger Charts
Sam Gatlin and his co-host examine momentum in precious metals and semiconductors, then use relative strength and anchored VWAP to distinguish leaders from weaker rebounds.
IDEAS / Tickers
SPDR S&P Biotech ETF

Sam Gatlin and his co-host examine momentum in precious metals and semiconductors, then use relative strength and anchored VWAP to distinguish leaders from weaker rebounds.

The November 27, 2025 Thanksgiving special paired a bullish metals outlook with unfinished energy and solar setups, then examined the risks beneath biotechnology's strength.

On November 25, 2025, the Piper Sandler technician challenged the case for an immediate year-end rally, identified the recovery that could change his mind and debated biotechnology and gold with JC Parets.

On November 24, 2025, Sam Gatlin and Alfonso DePablos examined healthcare leadership, Circle's possible rebound and the work still needed to repair several damaged charts.

The October 17, 2025 Morning Show split over the depth of equity-market weakness, while Louis Sykes described a crypto market still recovering from forced selling.

The August 14, 2025 Morning Show connected D-Wave’s low implied volatility with an unfinished chart setup, while Jason Krutzky explained how he followed competing memecoin launchpads.

The August 13, 2025 Morning Show paired a debate over crypto leadership with Thwaites’ biotech watchlist and Riley Rosebee’s argument for autonomous transport.

On July 31, 2025, Wald distinguished participation from leadership and explained why lagging small caps did not automatically make large-cap growth a sell.

The July 28, 2025 Chart Request Live compared unfinished reversals with established trends, using Moderna, Axis Capital, 3M and energy to define different conditions for participation.

The June 4, 2025 Morning Show paired Parets' conviction in the recovery with Strazza's concern about speculative stocks fading after strong news.

After Netflix, Disney and a biotech ETF failed his shorter-term trades, Lund described the intraday conditions he wanted to see improve before buying again. Mary Thwaites was also reducing short-term exposure while keeping longer-term positions.

After a sharp divergence between small stocks and megacaps, Singleton favored biotech and broader risk exposure. JC Parets pushed back on his preference for biotech and capital-market stocks over regional banks.

Technology and small caps were testing an old dividing line. Zarling found a clearer choice inside the small-cap index: biotechnology rather than regional banks.

Some U.S. operators were breaking a two-year pattern. Aurora Cannabis still couldn’t put in a higher low. Lund explained what an earlier loss had taught him about buying the industry’s story.

A breakout in small caps raised two possibilities for Brian Lund: money could rotate away from the leaders, or the laggards could join them. He was watching biotech for evidence.

Wald was comfortable with large technology stocks leading in November 2023. His concern was whether smaller companies could join the advance, with regional banks and software offering possible routes to broader strength.

The November rally had broadened, but Zaccardi was already watching for a change in leadership around the turn of the year. Retail, biotech and regional banks were on his list.

A viewer spotted a decade-long base in Marathon Oil. Parets saw an even longer one, but the strength he wanted was in Marathon Petroleum.

Guest host Jeff Hirsch came to the July 11, 2023 Morning Show with a summer playbook, a thin stock portfolio and a price he wanted to see before betting against industrials.